Angioblast intends to achieve this goal through the advancement of its three lead and groundbreaking product candidates that have each been proven to be effective in animal models of human CVD:
Allogeneic Adult Stem Cells: special allogeneic adult stem cells called Mesenchymal Precursor Cells (MPC)
-
Protein Therapeutics: peptide- based therapeutics that induce stem cell migration, angiogenesis, and cardiovascular recovery, the lead candidate being stromal-derived factor 1 (SDF-1)
-
Gene Silencing: delivered in drug-eluting stents for coronary and peripheral artery disease, consisting of RNA silencing technology, the lead candidate targeting the blood vessel and clotting regulator plasminogen activator inhibitor type I (PAI-1)
Each of the Company's lead products and underlying proprietary technology platforms (which are covered by an extensive patent portfolio) operates primarily by regulating blood vessel growth. Therefore, these lead product candidates and the related technologies are applicable to a broad range of diseases where new blood vessel growth may be useful, including congestive heart failure (“CHF”), myocardial infarction (heart attack, or “MI”), peripheral arterial disease (“PAD”) and skin ulcers.
